The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma Ltd. filed an offering circular supplement covering 1,490,000 common shares issuable upon exercise of its public warrants. The public warrants have a $4.64 exercise price, expire on November 15, 2029, and trade on Nasdaq under the symbol MDCXW, while the common shares trade as MDCX; on August 21, 2025, they closed at $2.45 and $0.93, respectively.
The attached report also discloses unregistered sales of 809,654 common shares to Yorkville under a Standby Equity Purchase Agreement, for approximate aggregate consideration of $1,651,464. Medicus plans to use part of the net proceeds to prepay a portion of debentures held by Yorkville. In addition, the chief financial officer exercised stock options for 145,000 common shares for cash, providing the company with approximately $156,250 in proceeds.
Medicus Pharma Ltd. reported recent unregistered equity sales and an insider option exercise. Under its Standby Equity Purchase Agreement with Yorkville, the company sold a total of 809,654 common shares between July 30 and August 21, 2025 for approximate aggregate consideration of $1,651,464. The company plans to use part of the net proceeds to prepay a portion of debentures outstanding with Yorkville.
In addition, on August 13, 2025, the Chief Financial Officer exercised stock options for 145,000 common shares, providing the company with aggregate cash proceeds of about $156,250. The company also noted a press release describing updates on its proposed Type C Meeting with the FDA and its second quarter 2025 financial highlights.
Schedule 13G amendment filed by Armistice Capital, LLC and Steven Boyd discloses a shared beneficial ownership of 935,724 common shares of Medicus Pharma Ltd., representing 4.99% of the class. The filing states Armistice Capital acts as investment manager to Armistice Capital Master Fund Ltd., the direct holder, and that Mr. Boyd, as managing member, may be deemed to beneficially own the shares. Voting and dispositive power are reported as shared (935,724 shares) with no sole voting or dispositive power.
Schedule 13G/A disclosure: This filing reports beneficial ownership in Medicus Pharma Ltd. by Dr. Kenneth Melani and Velocity Fund Partners, LP. Dr. Kenneth Melani directly holds 409,411 common shares. Velocity Fund Partners, LP directly holds 2,839,330 common shares, and the two Reporting Persons together report an aggregate beneficial ownership of 3,248,741 shares, representing 18.2% of the outstanding class. The Velocity position alone is reported as 2,839,330 shares (15.9%).
The cover-page entries state sole voting power and sole dispositive power of 3,248,741 shares for Dr. Melani and of 2,839,330 shares for Velocity Fund Partners. The percentages are calculated using 17,816,266 shares outstanding as reported by the Company in its Quarterly Report. The filing also notes that Dr. Melani "may be deemed" the beneficial owner of securities held by Velocity but expressly disclaims beneficial ownership except to the extent of his direct holdings. Exhibit 99.1 (Joint Filing Agreement) is incorporated by reference.
Medicus Pharma Ltd. Schedule 13G/A reports that SkinJect Partners LLC directly owns 800,952 common shares of Medicus Pharma, representing 4.5% of the outstanding common stock based on 17,816,266 shares reported by the company. The filing shows SkinJect Partners has sole voting and sole dispositive power over these shares.
John Hathaway is identified as a reporting person and may be deemed the beneficial owner of the shares held by SkinJect Partners LLC, though he disclaims beneficial ownership except to the extent of any direct ownership. The filing provides standard disclosure of ownership and power to vote or dispose.
Medicus Pharma Ltd. (MDCX) is a clinical-stage life sciences company focused on advancing a dissolvable doxorubicin microneedle array program (SkinJect) and opportunistic biotech acquisitions. The company reported $9,669,546 in cash and cash equivalents at June 30, 2025, up from $4,164,323 at year-end 2024, driven by equity offerings and warrant exercises.
Operating losses widened: a six-month net loss of $11,278,492 in 2025 versus $5,340,217 in 2024, producing an accumulated deficit of $40,182,395. Cash used in operations was $9,409,825 for the six months. The company closed a $4.17M Regulation A offering and a $7.01M June 2025 public offering, issued debentures for $4.5M (principal $5.0M) and entered a SEPA commitment for up to $15M. The company also agreed to acquire Antev Limited for consideration shares and contingent payments up to $65M. Management discloses substantial doubt about going concern and identified material weaknesses in internal controls.
On 4 Aug 2025 Medicus Pharma (MDCX) filed an 8-K announcing a non-binding Memorandum of Understanding (MoU) with Boston-based Helix Nanotechnologies. The parties intend to merge HelixNano’s proprietary mRNA vaccine platform with Medicus’ microneedle array (MNA) delivery technology to create thermostable, needle-free vaccines for infectious diseases.
The MoU outlines: (i) good-faith negotiations to form a joint venture for co-development and commercialisation; and (ii) an immediate collaborative project to manufacture clinical-grade MNA-loaded doses of HelixNano’s candidate HN-0001 for a Phase 1 bridging study comparing intramuscular versus intradermal delivery. Except for limited sections, the MoU is expressly non-binding; either party may withdraw until definitive agreements are executed. No financial terms, milestones, equity allocations or timelines were disclosed, and the filing contains no revenue or earnings data. A press release (Exhibit 99.1) accompanies the report, while Item 9.01 lists standard exhibit references.